BridgeBio's Breakthrough: Oral Drug Succeeds in Dwarfism Study
BridgeBio's oral infigratinib outperforms BioMarin's injectable therapy in boosting growth for kids with achondroplasia, marking a major win in treating the genetic cause of dwarfism.
/ 1659 items
#XY↓
Seres Therapeutics Shifts Focus to Promising New Programs
Seres Therapeutics announces pauses in some studies, workforce cuts, and a new emphasis on treatments for inflammatory and immune diseases like ulcerative colitis, aiming to extend cash through 2026.
Raymond James Upgrades Oscar Health to Outperform – Sees Big Upside
Raymond James upgrades Oscar Health stock to Outperform with $18 target, calling valuations attractive as margins improve in ACA market and forward outlook strengthens.
FDA Approves Novocure's Optune Pax: A New Hope for Pancreatic Cancer Patients
Novocure's Optune Pax wearable device wins FDA approval for locally advanced pancreatic cancer with gemcitabine + nab-paclitaxel. Phase 3 trial shows improved survival and delayed pain progression.
Viking Therapeutics Advances Oral Obesity Drug to Late-Stage Trials
Viking Therapeutics announces Phase 3 trials for its oral VK2735 obesity pill, showing up to 12.2% weight loss in early tests. Shares jump 9% as company eyes Q3 start.
FDA Rejects Review of Moderna's New mRNA Flu Vaccine: What Happened?
Vinay Prasad, FDA's biologics director, overruled staff to refuse reviewing Moderna's new mRNA flu vaccine, citing trial design issues. HHS denies overruling occurred amid ongoing debate on vaccine scrutiny.